CFTR and cystic fibrosis: These highly effective mutation-based pharmacotherapies are capable of correcting the basic defect of the CFTR protein but are still not eligible for all CF patients, principally for those that harbor rare or ultra-rare CFTR variants (10–15% of patients) whose responsiveness to modulators is still unknown [10].